Physician profile
Daniel A Riegel
NPI 1265792527
$8,219.81
in general payments reported to CMS, 2019-2025
44 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $708 · 2021: $1,658 · 2022: $1,476 · 2023: $1,093 · 2024: $1,251 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,565.93 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,106.86 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $590.48 | 2020-2025 | Verquvo |
| Medtronic, INC. | $485.50 | 2021-2024 | Selectsecure, Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $380.26 | 2020-2025 | |
| Medtronic Vascular, INC. | $336.18 | 2019 | |
| Esperion Therapeutics, INC. | $313.16 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $296.65 | 2019-2025 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $268.73 | 2021-2025 | |
| Amarin Pharma, INC. | $231.22 | 2019-2022 | |
| Lilly USA, LLC | $216.23 | 2020-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.08 | 2019-2025 | Jardiance |
| Amgen INC. | $197.24 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $185.85 | 2020-2025 | Farxiga, Airsupra |
| Alnylam Pharmaceuticals INC. | $178.69 | 2023-2025 | Amvuttra |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $177.28 | 2019-2021 | |
| Abbott Laboratories | $146.69 | 2019-2025 | Cardiomems, Mitraclip |
| Actelion Pharmaceuticals US, INC. | $126.37 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $124.95 | 2021-2024 | Rybelsus, Ozempic |
| Heartflow, INC. | $108.86 | 2023-2025 | Ffrct |
| Exact Sciences Corporation | $96.07 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $92.97 | 2021-2025 | |
| Cvrx, INC. | $80.33 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $78.65 | 2019 | |
| Edwards Lifesciences Corporation | $72.57 | 2021-2025 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $60.09 | 2025 | Ecc Solutions |
| Kiniksa Pharmaceuticals International, Plc | $47.68 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $44.97 | 2021-2023 | Shingrix |
| Scpharmaceuticals INC. | $44.47 | 2024 | |
| Hikma Pharmaceuticals USA | $33.39 | 2020 | |
| Corcept Therapeutics | $33.15 | 2023 | Korlym |
| Daiichi Sankyo INC. | $31.07 | 2022-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $28.56 | 2020 | |
| Atricure, INC. | $26.24 | 2021 | |
| Genentech USA, INC. | $23.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.87 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $21.16 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $20.86 | 2025 | Attruby |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.37 | 2025 | Edarbi |
| Arbor Pharmaceuticals, INC. | $18.67 | 2020 | |
| Dexcom, INC. | $18.22 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $17.59 | 2025 | Rhythm Express |
| Astellas Pharma US INC | $17.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Riegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.